Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7034148 | 0.86 | KCNH2 (0.40) | KCNH2KMT2AKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL7028528 | 0.86 | KMT2A (0.42) | KCNH2KMT2AALDH1A1 | |
| SCHEMBL7028529 | 0.86 | KMT2A (0.42) | KCNH2KMT2AALDH1A1 | |
| SCHEMBL7033247 | 0.85 | KCNH2 (0.44) | KCNH2KMT2AKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL7028336 | 0.84 | KCNH2 (0.47) | KCNH2KMT2AKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL7034946 | 0.84 | KDM4E (0.44) | KCNH2KMT2AKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL6994695 | 0.83 | KCNH2 (0.38) | KCNH2KMT2AKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL6742864 | 0.82 | KCNH2 (0.44) | KCNH2KMT2AALDH1A1MEN1MCHR1 | |
| SCHEMBL6622817 | 0.82 | LMNA (0.44) | KCNH2KMT2AKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL7036600 | 0.81 | KCNH2 (0.37) | KCNH2KMT2AKDM4EALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212095-A1 | New bispidine compounds and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212095-A1 | New bispidine compounds and their use in the treatment of cardiac arrhythmias | KCNH1, LBR, CACNA1E | KCNH2 7/4885KMT2A 2608/4885KDM4E 4058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.